Pharmaceutical

EASD 2024: Novo Nordisk’s Saxenda shows weight loss in children

Children aged 6-12 years achieved a 5.8% reduction in BMI with Novo Nordisk's Saxenda at 52 weeks in a Phase IIIa trial.

Sep 12, 2024 - 04:00
EASD 2024: Novo Nordisk’s Saxenda shows weight loss in children
Children aged 6-12 years achieved a 5.8% reduction in BMI with Novo Nordisk's Saxenda at 52 weeks in a Phase IIIa trial.
Read the original article

Tags:

Previous Article

IBA venture PanTera gains €134m in funding to scale up actinium-225 production

Next Article

NanoSyrinx secures funds to develop biologic therapeutics

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers

STAT+: FDA is blasted by advocates for pursuing a deal ...

Jan 4, 2024

IAVI and Biofabri sign deal for TB vaccine candidate development

IAVI and Biofabri sign deal for TB vaccine candidate de...

May 18, 2023

STAT+: Senate panel clears PBM reforms, safety-net hospital payments

STAT+: Senate panel clears PBM reforms, safety-net hosp...

Nov 9, 2023